Dokument: Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI
| Titel: | Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=68903 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20250304-094648-4 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Jannusch, Kai [Autor] Bruckmann, Nils-Martin [Autor] Morawitz, Janna [Autor] Boschheidgen, Matthias [Autor] Quick, Harald H. [Autor] Herrmann, Ken [Autor] Fendler, Wolfgang Peter [Autor] Umutlu, Lale [Autor] Stuschke, Martin [Autor] Hadaschik, Boris A. [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | Tumor staging, Prostate cancer, Positron-emission tomography, Magnetic resonance imaging | |||||||
| Beschreibung: | Objectives
To investigate the specific strengths of MRI and PET components in 68Ga-PSMA-11 PET/MRI for staging of patients with biochemically recurrent prostate cancer (PCa). Methods Patients with biochemical recurrence of PCa and contrast-enhanced whole-body 68Ga-PSMA-11 PET/MRI including a dedicated pelvic multiparametric MRI were included in this retrospective study. Imaging datasets of MRI and PET were evaluated separately regarding local PCa recurrence (Tr), pelvic lymph node metastases (N1), distant lymph node metastases (M1a), bone metastases (M1b), and soft tissue metastases (M1c) according to PROMISE version 1. Data evaluation was performed patient- and region-/lesion-based. Cox regression revealed a PSA of 1.69 ng/mL as a cut-off for subgroup analysis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were evaluated for each image component. Differences in staging accuracy were assessed using the Wilcoxon and McNemar test. Results Altogether 102 patients (mean aged 68 ± 8 years, median PSA 1.33 ng/mL) were included. PCa was found in 70/102 (68%) patients. Accuracy of MRI in the detection of Tr, N1, M + , M1a, and M1b was 100%, 79%, 90%, 97%, and 95% for PSA < 1.69 ng/mL and 100%, 87%, 87%, 91%, and 96% for PSA > 1.69 ng/mL. Accuracy of 68Ga-PSMA-11 PET was 93%, 97%, 93%, 98%, and 100% for PSA < 1.69 ng/mL and 87%, 91%, 96%, 100%, and 96% for PSA > 1.69 ng/mL. Conclusions Combined assessment of 68Ga-PSMA-11 PET/MRI improves tumor localization in men with biochemical recurrence. The MRI detected local recurrence of PCa more often whereas 68 Ga-PSMA-11 PET detected lymph node metastases more often, especially for PSA < 1.69 ng/mL. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Jannusch, K., Bruckmann, N.-M., Morawitz, J., Boschheidgen, M., Quick, H. H., Herrmann, K., Fendler, W. P., Umutlu, L., Stuschke, M., Hadaschik, B., Antoch, G., Schimmöller, L., & Kirchner, J. P. (2023). Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI. European Radiology. Publiziert. https://doi.org/10.1007/s00330-023-10442-4 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 04.03.2025 | |||||||
| Dateien geändert am: | 04.03.2025 |
